Company / Depreciation & Amortization
Insight Molecular Diagnostics Inc. Depreciation & Amortization History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$1.6M
FY2025
5-year range
$313.0K / $1.7M
FY2021-FY2025
Trend
-6.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Increased from $2M to $2M over the past 2 years.
Based on SEC 10-K filings.
$2M in FY2025 with a 5-year CAGR of +35.4%.
Increased from $2M to $2M over the past 2 years.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +25.0%
- 5-Year CAGR
- +35.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +35.4%, indicating consistent growth.
- In FY2025, depreciation & amortization decreased 6.9% year-over-year.
- Peak depreciation & amortization was recorded in FY2024.
- Lowest depreciation & amortization in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -7.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.6M | -6.9% |
| FY2024 | $1.7M | +9.9% |
| FY2023 | $1.5M | +91.0% |
| FY2022 | $800.0K | +155.6% |
| FY2021 | $313.0K | -9.0% |
| FY2020 | $344.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026